Earnings summaries and quarterly performance for cbdMD.
Executive leadership at cbdMD.
Board of directors at cbdMD.
Research analysts who have asked questions during cbdMD earnings calls.
Recent press releases and 8-K filings for YCBD.
cbdMD Announces Strategic Acquisition of Bluebird Botanicals
YCBD
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- cbdMD, Inc. (YCBD) announced the closing of the acquisition of substantially all of the assets of Bluebird Botanicals on January 14, 2026.
- The transaction was structured as an asset purchase involving an initial share issuance and earnout shares, which is expected to strengthen cbdMD's balance sheet.
- Management anticipates realizing operational efficiencies through consolidated supply chain, manufacturing, and shared services, and expects accelerated revenue growth from broadened product offerings and cross-brand distribution opportunities.
- The acquisition adds a differentiated portfolio of intellectual property and is projected to enhance cbdMD's revenue foundation, supporting its goal of achieving positive EBITDA and net income.
Jan 14, 2026, 2:00 PM
cbdMD, Inc. acquires Bluebird Botanicals assets
YCBD
M&A
New Projects/Investments
- On January 12, 2026, cbdMD, Inc. entered into an Asset Purchase Agreement to acquire substantially all assets of Gaia Botanicals, LLC (Bluebird Botanicals), CBD CliniLabs LLC, and Precision Botanical LLC.
- The acquisition includes the Bluebird Botanicals brand name, its online CBD marketplace, related trademarks, and inventory.
- The consideration for the acquisition comprises 425,000 shares of cbdMD's restricted common stock issued at closing, plus an earnout of up to 525,000 additional restricted shares based on Net Revenue performance.
- All issued shares are subject to a 180-day lock-up period, followed by a 365-day "Dribble Out Period" limiting sales to 125,000 shares per calendar quarterly period.
Jan 14, 2026, 2:57 AM
cbdMD, Inc. Reports Fiscal Year 2025 Results and NYSE American Compliance Resolution
YCBD
Earnings
Convertible Preferred Issuance
New Projects/Investments
- cbdMD, Inc. reported its third consecutive year of operating improvement in fiscal year 2025, reducing its operating loss by $1.2 million to approximately $2.1 million, and improving adjusted non-GAAP EBITDA from a $1.7 million loss in 2024 to a $900,000 loss in 2025. Net sales for FY 2025 totaled $19.1 million, a slight decrease from $19.5 million in the prior year, though Q4 2025 net sales increased 2% year-over-year to $4.7 million.
- The company significantly strengthened its balance sheet, increasing net book value from under $2 million to over $7 million and eliminating over $7 million in annual accrued preferred dividend obligations. Working capital improved to approximately $3.3 million as of September 30, 2025, from approximately -$1 million in the prior year.
- In December 2025, cbdMD received formal confirmation from the NYSE American that all prior compliance deficiencies had been fully resolved. The company is prioritizing growth investment in its new beverage brand, Oasis, which is distributed in nine states. Furthermore, a recent White House executive order exploring Medicare reimbursement for full-spectrum hemp-derived CBD products could create a $30 billion market opportunity, with a pilot program potentially starting April 1st.
Dec 19, 2025, 9:20 PM
cbdMD Reports Improved Fiscal Year 2025 Operating Results and Strengthened Balance Sheet
YCBD
Earnings
Revenue Acceleration/Inflection
Convertible Preferred Issuance
- cbdMD, Inc. (YCBD) reported a $2.1 million operating loss for fiscal year 2025, an improvement of $1.2 million from the prior year, marking its third consecutive year of operating improvement. Its adjusted non-GAAP EBITDA improved to a $900,000 loss in 2025 from a $1.7 million loss in 2024.
- For fiscal year 2025, total net sales were $19.1 million with gross margins at 63%. Q4 2025 net sales increased 2% year-over-year to $4.7 million, primarily due to a 25% increase in wholesale net sales.
- The company significantly strengthened its balance sheet, increasing net book value to over $7 million and improving working capital to approximately $3.3 million as of September 30, 2025. It also secured $2.25 million in additional financing and established a $20 million equity line of credit.
- In December 2025, YCBD resolved all prior NYSE American compliance deficiencies. The White House's recent executive order supporting Medicare reimbursement for hemp-derived CBD products could potentially impact 60 million Medicare consumers, signaling a positive shift in the regulatory environment.
Dec 19, 2025, 9:20 PM
YCBD Announces Fiscal Year 2025 Earnings and Regulatory Developments
YCBD
Earnings
Convertible Preferred Issuance
Delisting/Listing Issues
- cbdMD reported a fiscal year 2025 operating loss of $2.1 million, an improvement from a $3.3 million loss in 2024, and an adjusted non-GAAP EBITDA loss of $900,000, down from a $1.7 million loss in 2024. Fiscal year 2025 net sales were $19.1 million, a slight decrease from $19.5 million in the prior year.
- The company significantly strengthened its balance sheet, increasing net book value from under $2 million to over $7 million and improving working capital to $3.3 million as of September 30, 2025. cbdMD also secured $2.25 million in additional financing and established a $20 million equity line of credit.
- In December 2025, cbdMD received confirmation that all prior NYSE American compliance deficiencies were resolved. A recent White House executive order directs modernization of federal cannabis policy, including exploring Medicare reimbursement for full-spectrum hemp-derived CBD products, which could potentially open a $30 billion market.
- Operational focus includes expanding the Oasis beverage brand, now distributed across nine states, and prioritizing higher-margin products for its core cbdMD and Paw CBD brands.
Dec 19, 2025, 9:20 PM
cbdMD Regains NYSE American Listing Compliance
YCBD
Delisting/Listing Issues
Convertible Preferred Issuance
- cbdMD, Inc. (YCBD) has regained full compliance with the NYSE American continued listing standards, with the ".BC" indicator removed effective December 8, 2025.
- The company received formal notification from NYSE American on December 5, 2025, confirming the resolution of deficiencies under Sections 1003(a)(i) and (ii) of the Company Guide.
- CEO Ronan Kennedy stated that a successful Series A Preferred share conversion in May and a capital raise completed in September were essential components of their compliance strategy.
Dec 8, 2025, 9:35 PM
cbdMD Reports Preliminary Unaudited Fourth Quarter and Fiscal 2025 Results
YCBD
Earnings
Guidance Update
Revenue Acceleration/Inflection
- cbdMD, Inc. anticipates net sales revenue for fiscal 2025 to range between $19.1 and $19.3 million, compared to $19.5 million in fiscal 2024.
- For the fourth quarter of fiscal 2025, net sales revenue is expected to be between $4.7 and $4.9 million, an increase from $4.6 million in the fourth quarter of fiscal 2024.
- The company projects an improved Net Loss for fiscal 2025, narrowing from $3.7 million to a range of $1.9 to $2.1 million.
- CEO & CFO Ronan Kennedy noted positive sequential and year-over-year revenue growth in the fourth quarter and essentially flat year-over-year sales for the full fiscal year, driven by disciplined cost management and a focus on profitable growth.
- These financial results are preliminary and unaudited, and are subject to change.
Nov 25, 2025, 9:42 PM
Quarterly earnings call transcripts for cbdMD.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more